Point72 Asset Management L.P. Invests $1.48 Million in Alpha Teknova, Inc. (NASDAQ:TKNO)

Point72 Asset Management L.P. acquired a new position in shares of Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 306,427 shares of the company's stock, valued at approximately $1,483,000. Point72 Asset Management L.P. owned 0.57% of Alpha Teknova at the end of the most recent quarter.

Separately, Roubaix Capital LLC purchased a new stake in shares of Alpha Teknova during the third quarter worth approximately $2,015,000. Institutional investors own 13.81% of the company's stock.

Alpha Teknova Stock Performance

NASDAQ:TKNO traded down $0.23 during midday trading on Wednesday, reaching $7.76. The stock had a trading volume of 129,288 shares, compared to its average volume of 230,190. The company has a quick ratio of 3.94, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The stock has a market cap of $413.67 million, a P/E ratio of -10.49 and a beta of 0.37. The firm has a fifty day simple moving average of $6.72 and a two-hundred day simple moving average of $4.40. Alpha Teknova, Inc. has a 12-month low of $1.15 and a 12-month high of $8.91.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.04). The firm had revenue of $9.58 million during the quarter, compared to analysts' expectations of $9.30 million. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. During the same period in the previous year, the firm earned ($0.34) EPS. On average, equities analysts expect that Alpha Teknova, Inc. will post -0.58 EPS for the current year.

About Alpha Teknova

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.